|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research显示文摘Chemotherapy with improved effect in patients with metastatic pancreatic cancer has recently been established, launching a new era for patients with this very aggressive disease. FOLFIRINOX and gemcitabine plus nab-paclitaxel are different regimens, both capable of stabilizing the disease, thus increasing the number of patients who can reach second line and even third line of treatment. Concurrently, new windows of opportunity open for nutritional support and other therapeutic interventions, improving quality of life. Also pancreatic surgery has changed significantly during the latest years. Extended operations, including vascular/multivisceral resections are frequently performed in specialized centers, pushing borders of resectability. Potentially curative treatment including neoadjuvant and adjuvant chemotherapy is offered new patient groups. Translational research is the basis for the essential understanding of the ongoing development. Even thou biomarkers for clinical management of patients with periampullary tumors have almost been lacking, biomarker driven trials are now in progress. New insight is constantly made available for clinicians; one recent example is selection of patients for gemcitabine treatment based on the expression level of the human equilibrium nucleoside transporter 1. An example of new diagnostic tools is identification of early pancreatic cancer patients by a three-biomarker panel in urine: The proteins lymphatic vessel endothelial hyaluronan receptor 1, regenerating gene 1 alpha and translation elongation factor 1 alpha. Requirement of treatment guideline revisions is intensifying, as combined chemotherapy regimens result in unexpected advantages. The European Study Group for Pancreatic Cancer 4 trial outcome is an illustration: Addition of capecitabine in the adjuvant setting improved overall survival more than expected from the effect in advanced disease. Rapid implementation of new treatment options is mandatory when progress finally extends to patients with this serious disease. | Trond A Buanes | 2016 | World Journal of Gastroenterology2016，22，48： | 3 |
| 2 | Laparoscopic resection of exocrine carcinoma in central and distal pancreas results in a high rate of radical resections and long postoperative survival显示文摘 | Irina Pavlik Marangos Trond Buanes B?rd I. R?sok Airazat M. Kazaryan Arne R. Rosseland Krzysztof Grzyb Olaug Villanger ?ystein Mathisen Ivar P. Gladhaug Bj?rn Edwin | 2012 | Surgery2012，，5： | 3 |
| 3 | Role of surgery in pancreatic cancer显示文摘Treatment of pancreatic cancer is multimodal and surgery is an essential part,mandatory for curative potential.Also chemotherapy is essential,and serious postoperative complications or rapid disease progression may preclude completion of multimodal treatment.The sequence of treatment interventions has therefore become an important concern,and numerous ongoing randomized controlled trials compare clinical outcome after upfront surgery and neoadjuvant treatment with subsequent resection.In previous years,borderline resectable and locally advanced pancreatic cancer was most often considered unresectable.More effective chemotherapy together with the latest improvements in surgical expertise has resulted in extended operations,pushing the borders of resectability.Multivisceral resections with or without resection of major mesen-teric vessels are now performed in numerous patients,resulting in better outcome,recorded as overall survival and/or patient reported outcome.But postoperative morbidity increases concurrently,and clinical benefit must be carefully evaluated against risk of potential harm,associated with new comprehensive multimodal treatment sequences.Even though cost/utility analyses are deficient,extended surgery has resulted in signifi-cantly longer and better life for many patients with no other treatment alternative.Improved selection of patients to surgery and/or chemotherapy will in the near future be possible,based on better tumor biology insight.Clinically available biomarkers enabling personalized treatment are forthcoming,but these options are still limited.The importance of surgical resection for each patient’s prognosis is presently increasing,justifying sustained expansion of the surgical treatment modality. | Trond A Buanes | 2017 | World Journal of Gastroenterology2017，23，21： | 2 |
| 4 | Acute hyperglycemia altersmood state and impairs cognitive performance in people with type 2 diabetes显示文摘 | Andrew JS Ien JD Buan MF | 2004 | Diabetes Care2004，27，10： | 1 |
| 5 | Hypoxia-inducible factor and its biomedical relevance显示文摘 | Huang LE Buan HE | 2003 | J Biol Chem2003，278，19： | 1 |
| 6 | Intradermal Ras peptide vaccination with granulocyte macrophage colonystimulating factory as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma 显示文摘 | Gjertsen MK Buanes T Rosseland AR | 2001 | Int J Cancer2001，92，3： | 1 |
| 7 | Stakeholder participation in Norwegian coastal zone pianning显示文摘 | BUANES A JENTOFT S MAURSTAD A | 2005 | Ocean & Coastal Management2005，48，9： | 1 |
| 8 | Pancreatic carcinoma:MR,MR angiography and dynamic helical CT in the evaluation of vascular invasion显示文摘 | Arslan A Buanes T Geitung JT | 2001 | Eur J Radiol2001，38，2： | 1 |
| 9 | Subcategories of the derived category and eotilting complexes显示文摘 | Buan A | 2001 | Colloq Math2001，88，： | 1 |
| 10 | Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant : Clinical and immunological responses in patients with pancre- atic adenocareinoma显示文摘 | Gjertsen MK Buanes T Rosseland AR | 2001 | Int J Cancer2001，92，3： | 1 |
| 11 | Nitric oxide modulates the activities of plasma membrane H^+ - ATPase and PPase in wheat roots and promotes the salt tolerance against salt stress显示文摘 | Buan H H Shen W B Xu L L | 2004 | Acta Botanica Sinica2004，46，： | 1 |
| 12 | In whose interest? An exploratory analysis of stakeholders in Norwegian coastal zone planning 显示文摘 | Buanes A Jentoft S Karisen G R | 2004 | Ocean & Coastal Management2004，47，： | 1 |
| 13 | Intradermal RAS peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:clinical and immunological responses in patients with pancreatic adenocarcinoma显示文摘 | Buanes T Rosseland AR Bakka A Gladhaug I Soreide O | 2001 | Int J Cancer2001，92，3： | 1 |
| 14 | Pancreatic carcinoma:MR,MR angiography and dynamic helical CT in the evaluation of vascular invasion显示文摘 | Arslan A Buanes T Geitung JT | 2001 | Eur J Radiol2001，38，： | 1 |
| 15 | Intradermal ras peptide vaccination with granulocyte-macrophage colony stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinorna显示文摘 | Gjertsen MK Buanes T Rosseland AR | 2001 | Int J Cancer2001，92，3： | 1 |
| 16 | Tilting theory and cluster eombinatorics显示文摘 | Buan A Marsh R Reineke R | 2006 | Adv Math2006，204，： | 1 |
| 17 | Cluster structure for 2-Calabi-Yau categories and unipotent groups显示文摘 | Buan A Iyama O Reiten I | 2009 | Compos Math2009，145，4： | 1 |
| 18 | Acute hyper-glycemia altersmood state and impairs cognitive perfor-mance in people with type2 diabetes 显示文摘 | ANDREW J S ICN J D’BUAN M F | 2004 | Diabetes Care2004，27，10： | 1 |
| 19 | Keratins 8, 10, 13, and 17 are useful markers in the diagnosis of human cervix carcino- mas显示文摘 | Carrilho C Alberto M Buane L | 2004 | Hum Pathol2004，35，5： | 1 |
| 20 | Keratins 8, 10, 13, and 17 are useful markers in the diagnosis of human cervix carcinomas 显示文摘 | Carrilho C Alberto M Buane L | 2004 | Hum Pathol2004，35，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员